Risk factors for type 2 diabetes in groups stratified according to metabolic syndrome: a 10-year follow-up of The Tromsø Study by Joseph, Josepha et al.
DIABETES
Risk factors for type 2 diabetes in groups stratiﬁed according
to metabolic syndrome: a 10-year follow-up of The Tromsø Study
Josepha Joseph • Johan Svartberg •
Inger Njølstad • Henrik Schirmer
Received: 18 June 2010/Accepted: 15 December 2010/Published online: 28 December 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Many incident cases of type 2 diabetes do not
fulﬁl the metabolic syndrome, which accordingly has been
questioned both as a research and clinical tool. The aim of
this study was to determine differences in risk factors for
type 2 diabetes between groups with high or low metabolic
score. The study population were 26,093 men and women
attending the Tromsø Study in 1994, followed through
2005, and who did not have diabetes when entering the
study. A total of 492 incident cases of type 2 diabetes were
registered. A metabolic score was deﬁned according to a
modiﬁed version of the National Cholesterol Education
Program Adult Treatment Panel III. For those fulﬁll-
ing C 3 metabolic score criteria, increasing age, body mass
index (BMI), triglycerides and a family history of diabetes
were independent predictors. Age, BMI, and triglycerides
predicted type 2 diabetes more strongly in subjects with
low metabolic score, whereas high HDL cholesterol was
not protective in this low risk group. The risk associated
with a positive family history was unaffected by level of
metabolic score. In addition smoking, low education and in
men also physical inactivity were independent risk factors
only in those with low metabolic score. Adding these non-
metabolic risk factors increased correct classiﬁcation from
an ROC area of 77.2 to 87.1% (P value\0.0001). One
half of the incident cases of type 2 diabetes were missed by
using high metabolic score for risk prediction.
Keywords Type 2 diabetes  Metabolic syndrome  Low
metabolic score  High metabolic score  Non-metabolic
risk factors  Receiver operating characteristics
Abbreviations
BMI Body mass index
BP Blood pressure
CVD Cardiovascular disease
CI Conﬁdence interval
GAD Glutamic acid decarboxylase
HbA1c Glycated haemoglobin
HR Hazard ratio
HDL High-density lipoprotein
LTPA Leisure-time physical activity
NCEP National Cholesterol Education Program
ROC Receiver operating characteristics
SD Standard deviation
Introduction
The concept of metabolic syndrome was introduced to
improve identiﬁcation of risk of cardiovascular disease
(CVD) [1], but has failed to improve the detection of
cardiovascular risk beyond ordinary risk scores [2]. As a
predictor of type 2 diabetes, metabolic syndrome has
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DOI 10.1007/s10654-010-9540-7proved more useful [3], but due to the dichotomous use of
risk factors that in reality represent a continuum of risk, it
has been less useful than scores using multiple levels of
risk [4].
According to a joint statement by the American Diabetes
Association and the European Association for the Study of
Diabetes, it is suggested that health-care providers should
avoid labelling patients with the term metabolic syndrome,
because this might create the impression that the metabolic
syndrome denotes a greater risk than its components, or
that it is more serious than other cardiovascular disease risk
factors, or that the underlying pathophysiology is clear [5].
Accordingly, a report of WHO experts suggested to drop
the concept both for clinical and research purposes [6]. The
concept initially intended to generate research hypotheses,
has been used for identiﬁcation of subjects at risk and has
thereby probably distracted attention from other risk fac-
tors of type 2 diabetes.
The aim of this study was to evaluate the risk factors of
type 2 diabetes in groups stratiﬁed according to metabolic
score and evaluate whether diabetes in subjects with low
metabolic score were more likely to be detected by other
risk factors.
Materials and methods
Study design and population
The Tromsø Study is a multipurpose single-centre popu-
lation based prospective study with repeated health surveys
among inhabitants of the Tromsø municipality, Northern
Norway [7]. All residents born 1969 or earlier were invited
to the fourth Tromsø survey in 1994/95. Altogether 27,158
(77%) out of an eligible population of 35,420 subjects,
participated. Subjects not consenting to medical research
(n = 201), subjects with a prior diagnosis of type 2 dia-
betes (n = 336), unknown type 2 diabetes (45), type 1
diabetes (n = 81), uncertain type of diabetes during follow
up (n = 91), uncertain year of diagnosis (n = 142) and
subjects with missing values for any metabolic syndrome
criteria and other relevant risk factors (n = 169), were
excluded, leaving 26,093 to be included in this study.
Subjects were followed from the date of enrolment (1994/
95) through December 31st, 2005. The median follow up
time was 10.8 years.
A subgroup of 7,160 comprising those aged 55–74 years
and 5–10% of those 25–54 and 75–85 years of age were
invited to a second visit a few weeks after the main survey;
this gave additional baseline information on waist cir-
cumference, non-fasting glucose and HbA1c and the pos-
sibility to estimate the prevalence of unknown diabetes. In
2001, 7,064 of the original cohort of the 1994/95 survey
participated in the ﬁfth Tromsø survey. This enabled us to
evaluate the change in risk factors from 1994 to 2001.
The screening included a self administered question-
naire concerning treatment for hypertension, smoking
habits and level of leisure-time physical activity (LTPA).
The questionnaire was checked by trained nurses. Physical
inactivity was deﬁned as less than 3 h per week of light
activity in leisure time without sweating or dyspnoea.
Moderate LTPA was deﬁned as 3 h or more of light
activity or 1–2 h of hard LTPA which caused sweating or
dyspnoea per week. Hard LTPA was deﬁned as hard
activity with sweating or becoming out of breath for 3 h or
more per week [8].
Educational level was deﬁned having completed 1:
primary and secondary-school, 2: high school or vocational
school 1–4 years, 3: university less than 4 years and 4:
4 years or more.
Family history of diabetes was reported as ﬁrst degree
family members, i.e. parents or siblings, with a history of
diabetes. Smoking status was ascertained as current, pre-
vious or never smoker.
Height and weight were measured at screening with
light clothing, and body mass index (BMI) was com-
puted as kg/m
2. Waist circumference was measured in
centimetres. Blood pressure was recorded in the sitting
position after 2 min’ rest by the use of an automatic
blood pressure measurement device (Dinamap Vital
Signs Monitor, Waukesha, WI, US). Three recordings
were taken at 2-min intervals, and the mean of the two
last readings were used in this analysis. The participant
was considered to have hypertension if he or she had
systolic blood pressure (BP) C 130 mmHg or diastolic
BP C 85 mmHg at screening, or reported being on
antihypertensive medication.
Non-fasting blood samples were collected from an
antecubital vein, serum prepared by centrifugation after
one hour respite at room temperature, and analyzed at the
Department of Clinical Chemistry, University Hospital of
North Norway. Serum total cholesterol and triglycerides
were analyzed by enzymatic colorimetric methods and
commercially available kits (CHOD-PAP for cholesterol
and GPO-PAP for triglycerides: Boeringer Mannheim).
Serum HDL-cholesterol was measured after precipitation
of lower-density lipoproteins with heparin and manganese
chloride. Determination of glycosylated haemoglobin
(HbA1c) in EDTA whole blood was based on an immu-
noturbidometric assay (UNIMATES, F. Hoffmann-La
Roche AG: Basel, Switzerland).
Deﬁnition of metabolic score
A metabolic score was deﬁned according to a modiﬁed
version of the National Cholesterol Education Program
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123(NCEP) Adult Treatment Panel III [9], in which the met-
abolic syndrome is present when three or more of the
following criteria are fulﬁlled.
1. Hypertension; BP C 130/85 mmHg and/or antihyper-
tensive medication.
2. Hypertriglyceridemia; fasting serum triglycerides[
1.70 mmol/L.
3. Low high-density lipoprotein (HDL) cholesterol;
below 1.03 mmol/L in men and\1.29 mmol/L in
women.
4. Central obesity; waist circumference[102 cm (men),
[88 cm (women).
5. Fasting plasma glucose C 6.1 mmol/L.
Because waist circumference measurements were
available only for a subset of participants, BMI was used
instead of waist circumferences in the metabolic score, as
suggested as a possible alternative in other studies [10, 11].
In our study, the cut off values for BMI were calculated as
the mean BMI values in men and women with waist cir-
cumference of 102 and 88 cm, respectively. Accordingly,
BMI[28.3 kg/m
2 for men and[27.0 kg/m
2 for women
were used. The last criterion; fasting plasma glucose was
not available and not included in the analysis.
Subjects were given a score from 0 to 4 for each fulﬁlled
feature of the metabolic syndrome (based on the modiﬁed
NCEP deﬁnition) and grouped according to number of ful-
ﬁlled features. A score of C 3 fulﬁlled criteria was labelled
‘‘high metabolic score’’. Conversely, those with 2 or less
fulﬁlled criteria were labelled ‘‘low metabolic score’’.
Follow-up and case identiﬁcation
Possible cases of diabetes mellitus were identiﬁed through
self-reported diabetes in questionnaires or HbA1c[6.5%
in the health surveys 1994/95 or 2001, and through linkage
of the Tromsø Study participant list to diabetes related
discharge diagnoses in the digital patient records at the
only local hospital (ICD- 9 codes 250, 357.2, 362.0, 583.8,
648.0, 648.8, 790.2, ICD-10 codes E10 -E14, O24 and
R73). Some cases of hospital conﬁrmed diabetes, but with
no diabetes-related discharge diagnosis, were detected
through our adjudication process for cardiovascular dis-
eases. We validated all possible cases of diabetes by
checking their medical records. Cases were classiﬁed as
having no diabetes, type 1 or type 2 diabetes, based on
glucose measurements if they had non-fasting glu-
cose C 11.1 mmol/L, fasting glucose[7.0 mmol/L, 2 h
glucose load C 11.1 mmol/L or HbA1c C 7.0% in the
hospital laboratory database or recorded use of insulin or
oral anti-diabetic drugs [12, 13]. C-peptide measurement
was the common method at the hospital during the follow-
up period to differentiate between type 1 and type 2
diabetes, while Glutamic acid decarboxylase antibody
(anti-GAD) measurements were performed in a minority of
cases. Follow up ended December 31st, 2005.
Study approval
This study has been approved by the Regional Committee
for Medical and Health Research Ethics, Northern Norway
and all participants included have given written informed
consent to scientiﬁc use of data and linkage to health
registries.
Statistical analysis
Data are presented stratiﬁed by gender. Differences in
means between groups were tested using age adjusted
general linear models. Categorical variables were tested
with logistic regression. As cases were diagnosed with
diabetes throughout the follow up period, hazard ratios
(HR) for diabetes were calculated using Cox proportional
hazard models adjusting for age and all the other variables.
To evaluate differences in HR estimates between sub-
groups, interaction terms between risk factor and sub-
groups were tested. The proportional hazard assumption
was examined using log minus log plots and evidence of
non-proportionality were not found. Preliminary analyses
revealed signiﬁcant interactions between sex and BMI and
between sex and triglycerides. Accordingly, all analyses
were sex stratiﬁed. ROC areas were computed for presence
of high metabolic score univariably, in multivariable
analysis with the metabolic syndrome factors as continuous
variables, and in a full model with all signiﬁcant predictors
entered in a logistic regression model. Signiﬁcance tests
were two-tailed, and the signiﬁcance level was chosen at
5%. Estimations of differences between ROC areas were
performed in SAS statistical software (SAS Institute, Cary,
NC, USA) version 9.2 using the roc and roccontrast
statement in proc logistic. All other analyses were per-
formed using SPSS version 17 (Statistical Package for
Social Sciences, Chicago, IL, USA, 2009).
Results
In the total study population aged 25–98 years and without
diabetes at baseline (n = 26,093), 492 new cases of type 2
diabetes were identiﬁed during follow up, 294 in men and
198 in women.
Table 1 shows age adjusted baseline characteristics of
those who remained free of diabetes and those who
developed type 2 diabetes during follow-up and who were
with or without metabolic syndrome at baseline. Of the
26,093 subjects, 3,684 had a high metabolic score, i.e.
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(95%CI 15–17%) in men and 13% (95%CI 12–14%) in
women. As shown, only 53% of incident cases of type 2
diabetes had a high metabolic score at baseline (47% of
men and 62% of women). Those with a low metabolic
score were more likely to be older, less educated and more
inactive and smoke more than the other two groups.
Otherwise, the low score group had a mean BMI, triglyc-
erides and antihypertensive treatment signiﬁcantly higher
than those not developing diabetes, and signiﬁcantly lower
than the high score group.
For those fulﬁlling C 3 metabolic syndrome criteria,
age, BMI, triglycerides, and a family history of diabetes
were independent predictors of diabetes (Table 2). Of these
risk factors age, BMI, and triglycerides predicted type 2
diabetes more strongly in subjects with low metabolic
score. HDL cholesterol showed a protective effect only in
women with a high metabolic score. The risk associated
Table 1 Baseline characteristics in men and women initially free from diabetes, by future diabetes and metabolic status
Variables Men Women
Non
diabetics
(n = 12,104)
New cases of type 2 diabetes
(n = 294)
Non
diabetics
(n = 13,497)
New cases of type 2 diabetes
(n = 198)
Low metabolic
score (n = 157)
High metabolic
score (n = 137)
Low metabolic
score (n = 76)
High metabolic
score (n = 122)
Age (years) 46.1 ± 0.13 58.1 ± 0.85*** 54.1 ± 0.89***
 46.5 ± 0.13 59.1 ± 1.59*** 57.6 ± 1.02***

Systolic blood pressure (mmHg) 137 ± 0.15 145 ± 1.55 153 ± 1.62***
 131 ± 0.18 146 ± 2.67 158 ± 2.14***

Diastolic blood pressure (mmHg) 79.7 ± 0.11 86.1 ± 0.94 91 ± 1.11***
 76.1 ± 0.11 82.5 ± 1.54 87.3 ± 1.69***

BMI (kg/m
2) 25.5 ± 0.03 27.5 ± 0.31*** 30.8 ± 0.28***
 24.6 ± 0.03 27.2 ± 0.57*** 31.3 ± 0.45***

Total cholesterol (mmol/l) 6.03 ± 0.01 6.5 ± 0.09 6.7 ± 0.09*** 5.94 ± 0.12 6.65 ± 0.14 6.86 ± 0.11**
HDL cholesterol (mmol/l) 1.35 ± 0.02 1.35 ± 0.02 1.07 ± 0.21***
 1.64 ± 0.01 1.69 ± 0.04 1.24 ± 0.03***

Triglycerides (mmol/l) 1.75 ± 0.01 1.82 ± 0.09* 3.42 ± 0.18***
 1.31 ± 0.01 1.46 ± 0.07* 2.81 ± 0.11***

Positive family history
of diabetes n (%)
1,372 (11.3) 39 (24.8)*** 32 (23.4)*** 1,804 (13.4) 25 (32.9)*** 39 (31.7)***
Anti-hypertensive treatment n (%)
Current 658 (5.4) 25 (15.9)* 40 (29.2)***
 743 (5.5) 11 (14.5)* 29 (23.7)***

Previous 268 (2.3) 6 (3.8) 2 (1.5) 358 (2.7) 5 (6.6) 13 (10.7)**
Never 11,178 (92.3) 126 (80.3) 95 (69.3) 12,396 (91.8) 60 (78.9) 80 (65.6)
Education n (%)
Primary/secondary 5,961 (49.2) 94 (59.9)* 73 (53.3) 6,546 (48.5) 48 (63.2)* 72 (59.0)
High school 1,526 (12.7) 18 (11.5) 21 (15.3) 2,301 (17.1) 10 (13.2) 15 (12.3)
College/university\4 years 2,256 (18.6) 21 (13.4) 20 (14.6) 2,489 (18.4) 10 (13.2) 17 (13.9)
College/university C 4 years 2,361 (19.5) 24 (15.2) 23 (16.8) 2,161 (16.0) 8 (10.4) 18 (14.8)
Leisure-time physical activity level n (%)
Hard 1,828 (15.1) 16 (10.2) 16 (11.7) 1,998 (14.8) 6 (7.9) 15 (12.3)
Moderate 6,781 (56.0) 53 (33.7) 70 (51.1) 6,305 (46.7) 19 (25.0) 35 (28.7)
Inactive 3,495 (28.9) 88 (56.1)** 51 (37.2) 5,194 (38.5) 51 (67.1)* 72 (59.0)
Daily smoking n (%)
Current 4,593 (37.9) 92 (58.6)*** 65 (47.4) 5,027 (37.2) 39 (51.3)*** 45 (36.9)
Previous 3,756 (31.1) 40 (25.5) 40 (29.2) 2,944 (21.8) 13 (17.1) 19 (15.6)
Never 3,755 (31.0) 25 (15.9) 32 (23.4) 5,526 (41.0) 24 (31.6) 58 (47.5)
The Tromsø Study 1994–2005
Values are means ± standard error or n (percentage)
Low metabolic score:\3 metabolic syndrome criteria fulﬁlled
High metabolic score: C 3 metabolic syndrome criteria fulﬁlled (metabolic syndrome)
BMI Body mass index, HDL cholesterol high density lipoprotein cholesterol
*P\0.05, **P\0.01, ***P\0.0001, age adjusted in analysis of covariance for continuous variables and logistic regression for categorical
variables comparing non-diabetics with either low or high metabolic score
 P for differences between low and high metabolic score, obtained by age adjusted analysis of covariance or logistic regression where
appropriate
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123with a positive family history was unaffected by metabolic
score. In addition hypertension, smoking, low education
and in men also inactivity, were independent risk factors
only in those with a low metabolic score. Adding these
non metabolic risk factors increased correct classiﬁcation
signiﬁcantly (ROC area increased from 77.2 to 87.1%;
P value\0.0001).
The risk of type 2 diabetes increased by increasing
number of fulﬁlled components of the metabolic score
(Fig. 1). The absolute risk of developing type 2 diabetes
over 10.8 years increased from 0.5% in men and 0.1% in
women to 9.2 and 9.8%, in those fulﬁlling zero to 4 met-
abolic score criteria, respectively. The age adjusted HR for
highest metabolic score compared to lowest metabolic
score were 16 (95% CI 8.6–31) for men and 52 (95% CI
23–119) for women. Adjusting for other risk factors such
as smoking, physical inactivity, education and a family
history of diabetes did not attenuate the point estimates of
risk in men, but the HR in women was reduced to 45 (95%
CI, 20–102). Although identifying a high risk group, our
dichotomized metabolic score deﬁnition only identiﬁed
53% of cases (ROC area 69.8% (95%CI 67.5–72.0%),
whereas a model using the same risk factors as continuous
variables correctly classiﬁed 81.5% (95%CI 79.7–83.3%).
Adding age, gender, inactivity, low education, a positive
family history and smoking increased correct classiﬁcation
to an ROC area of 86.7% (95%CI 85.5–88.2), both dif-
ferences P values\0.0001.
A sub-group of the total cohort who participated in the
1994 survey (n = 7160) were invited to a second screening
Table 2 Risk factors for type 2 diabetes by low and high metabolic score
Variables Men (294 cases) Women (198 cases)
Low metabolic
score
High metabolic
score
P value for
difference in
HR between
groups
Low metabolic
score
High metabolic
score
P value for
difference in
HR between
groups
HR (95% CI)
n = 10,426
HR (95% CI)
n = 1,972
HR (95% CI)
n = 11,983
HR (95% CI)
n = 1,712
Cases of type 2 diabetes (n) 157 137 76 122
Age (10 years) 1.76 (1.64, 2.11) 1.54 (1.36, 1.79) 0.000 1.54 (1.82, 1.8) 1.29 (1.12, 1.48) 0.003
BMI (1SD) 2.28 (1.98, 2.75) 1.59 (1.38, 1.84) 0.000 1.68 (1.40, 2.01) 1.52 (1.30, 1.78) 0.007
Triglycerides (1SD) 1.36 (1.14, 1.64) 1.16 (1.09, 1.23) 0.000 1.34 (1.07, 1.68) 1.17 (1.04, 1.32) 0.000
HDL cholesterol (1SD) 1.02 (0.76, 1.12) 1.01 (0.78, 1.14) – 1.06 (0.82, 1.36) 0.75 (0.58, 0.97) 0.000
Hypertension (yes) 1.47 (1.01, 2,15) 0.69 (0.35, 1.41) 0.001 1.86 (1.05,3.30) 1.53 (0.69, 3.42) 0.004
Family history (yes) 2.19 (1.51, 3.16) 2.07 (1.40, 2.98) – 2.54 (1.57,4.12) 2.25 (1.55, 3.26) –
Education
College/university C 4 years 1.00 1.00 – 1.00 1.00 –
College/university\4 years 0.95 (0.53, 1.72) 1.01 (0.61, 2.02) 1.11 (0.43, 2.83) 0.84 (0.45, 1.75)
High school 1.07 (0.59, 2.01) 1.11 (0.61, 2.01) 1.22 (0.47, 3.12) 0.89 (0.49, 1.87)
primary and secondary 1.81 (1.19, 2.88) 1.53 (0.77, 1.96) 1.75 (1.09, 4.57) 1.04 (0.69, 1.98)
Leisure-time physical activity
Hard 1.00 1.00 – 1.00 1.00 –
Moderate 0.81 (0.47, 1.39) 0.98 (0.57, 1.70) 0.91 (0.38, 2.10) 0.43 (0.34, 1.22)
Inactive 1.94 (1.18, 3.36) 1.10 (0.57, 1.79) 1.70 (0.91, 4.33) 0.48 (0.38, 1.28)
Smoking
Never 1.00 1.00 – 1.00 1.00 –
Previous 0.70 (0.42, 1.17) 0.61 (0.38, 1.22) 1.10 (0.56, 2.07) 0.76 (0.45, 1.28)
Current 1.68 (1.23, 4.25) 1.33 (0.91, 2.14) 1.56 (1.18, 4.18) 1.41 (0.89, 2.47)
The Tromsø Study 1994–2005
Cox’ proportional hazard regression analysis, multivariably adjusted
Low metabolic score: less than 3 metabolic score criteria fulﬁlled
High score: 3 or more metabolic score criteria fulﬁlled
For dichotomous variables; HR are given for answering ‘yes’ with ‘no’ as reference
For continuous variables; HR is given for a SD change in the variable
BMI Body mass index, CI conﬁdence interval, HDL high density lipoprotein, HR hazard ratio, SD standard deviation
Differences in HR between groups were determined using interaction terms between variable and group
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diabetes in the questionnaire at baseline. In addition we
detected 45 subjects with unknown diabetes as detected by
HbA1c C 7.0% in 1994. Of these 45, two had non-fasting
glucose[11.0 mmol/L. The 45 with unknown type 2
diabetes constituted 33% of a total of 138 with type 2
diabetes at baseline. One of these was detected by our
hospital validation.
Those attending this second phase were invited to a new
screening in 2001. Of those with a low metabolic score at
baseline and who developed type 2 diabetes after 2001,
97% had changed unfavourably in one or more risk factors
before developing type 2 diabetes, but only 36% had an
unfavourable change in 3 or more factors, resulting in 35%
(95% CI 33–37%) being reclassiﬁed to a high metabolic
score before the detection of type 2 diabetes. Of the low
score group who did not develop diabetes, 91% (95% CI
90–92%) changed unfavourably in one or more risk factors,
but only 11% (95% CI 7–15%) changed to the high score
group during follow up.
Discussion
Our study shows how the ‘‘metabolic syndrome’’, used as a
dichotomously deﬁned exposure variable—although iden-
tifying a high risk group, misses half of the incident cases of
type 2 diabetes. We found a signiﬁcantly better detection of
casesbyaddingafamilyhistoryoftype2diabetes,smoking,
low education and physical inactivity to the risk assessment
especially among those with a low metabolic score.
Our study showed an increasing risk of type 2 diabetes
with increasing number of metabolic features in accor-
dance with other prospective studies where the relationship
between similar features of metabolic syndrome and type
2 diabetes have been analysed [10, 14, 15]. In accor-
dance with other studies, we also found that the use of
dichotomous risk factors gave signiﬁcantly weaker pre-
diction of incident cases of type 2 diabetes than using the
metabolic risk factors as continuous variables [4, 15]. Our
study strongly indicates a continuous risk associated with
all metabolic syndrome features, also below established
cut-off values for metabolic syndrome. That those who do
not fulﬁl the criteria at baseline are older, and consequently
could have worsened in metabolic proﬁle more slowly,
might indicate a need for longer exposure time for those
with lower risk factor levels. In both men and women, low
risk subjects were signiﬁcantly older when they developed
diabetes compared to high risk subjects. In particular, this
was shown for women who had signiﬁcantly longer follow
up time as compared to men before development of dia-
betes if low in metabolic score. A difference in suscepti-
bility to changes in BMI could be the cause of these
observed gender differences. It has been shown that men
are more susceptible to an increase in blood pressure given
an increase in BMI than are women [16]. Changes in risk
factors have been shown to be independent predictors of
diabetes risk [17]. Accordingly, we also found worsening
of metabolic risk factors in 97% of low risk subjects who
subsequently developed type 2 diabetes.
Furthermore our study strongly indicates that life style
risk factors such as physical inactivity, smoking, educa-
tional level and also family history of diabetes should be
included when assessing diabetes risk. A recent review of
tools for predicting risk of type 2 diabetes in daily practice,
concluded that the Finnish Diabetes Risk Score (FIND-
RISC) which included all these risk factors except educa-
tional level, showed the highest ROC area (ROC 87%)
compared to metabolic syndrome which had only an ROC
of 83% [18]. Similarly our study showed that adding these
non-metabolic risk factors increased correct classiﬁcation
signiﬁcantly to a similar ROC (87%). Studies with a mul-
tifactorial approach to diabetes risk assessment conclude
that the concept of metabolic syndrome has a limited
practical utility as a diagnostic or management tool in case
of diabetes or CVD [6, 19].
As metabolic syndrome factors are differently distrib-
uted among men and women, we ﬁnd that HDL cholesterol
is a protective factor only among women with a high
metabolic score, although earlier studies have shown a
signiﬁcant lowering of risk for increasing HDL cholesterol
in both men and women [8]. We have earlier shown that
this is due to an interaction between HDL cholesterol, BMI
and triglycerides most pronounced in women where the
protective effect of HDL increased by increasing triglyc-
eride levels and more so at high BMI levels corresponding
to the high score group as deﬁned in the present article.
This indicates that the deﬁnition of a metabolic syndrome
does not describe a uniﬁed syndrome as such, but a com-
plex of related risk factors.
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Fig. 1 Age adjusted HR of type 2 diabetes for increasing metabolic
score with 95% conﬁdence intervals. The Tromsø Study 1994–2005.
The absolute 10-year risk of type 2 diabetes (%) is presented in the
table underneath
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123Our ﬁnding of hypertension being an independent risk
factor for type 2 diabetes only in those with a low meta-
bolic score, does not indicate a lack of risk of type 2 dia-
betes in the high risk group, only that this risk is better
identiﬁed through increasing levels of the other risk factors
age, BMI, triglycerides, smoking and a positive family
history of type 2 diabetes. Most of those high risk indi-
viduals had elevated blood pressure as shown in Table 1.
Our ﬁndings indicate that the degree of elevation does not
carry an independent risk within this subgroup.
Strengths and limitations
The study was conducted in a general population and
included a large number of men and women with a wide
age range at baseline and had a long follow-up. The veri-
ﬁcation process of diabetes cases was thorough, and
included the use of questionnaires, hospital records, and
laboratory reports. In addition, the case veriﬁcation has
been conducted at the only hospital in this region.
The limitation of this study is a lack of a baseline
screeningfordiabetes,i.e.;byfasting plasma glucoseororal
glucose tolerance test. The use of hospital records to adju-
dicate type 2 diabetes might further introduce a bias, as
subjects with well controlled diabetes detected and attended
by their general practitioner only, would be missed. As the
hospital laboratory serves also the general practitioners of
Tromsø, a proportion of those patients would be identiﬁed
through HbA1c measurements recorded in the hospital
database, but many general practitioners have their own
HbA1ckit.Inthesubgroupof7,160participantswithHbA1c
and non-fasting glucose measured in a second phase of the
baseline screening, there were 45 subjects with unknown
type 2 diabetes not detected by our validation. This consti-
tutes 33% of all with diabetes at baseline. Including HbA1c
measurements at baseline to deﬁne prevalent diabetes,
increased the yield of unknown diabetes substantially from
23%inaprevious studyinourpopulationusingonlyHbA1c
registeredatthehospital[17].Amongthose19,495Tromsø4
participants who did not take part in the second phase of the
screening in 1994, there were 246 probable cases of pre-
valent type 2 diabetes. Given the same prevalence of
unknown diabetes in this younger population we probably
had 116 undetected cases of diabetes at baseline weakening
ourchanceofﬁndingassociations.Asthecontrolgroupisso
largeitisunlikelythattheseundetectedcaseshaveincreased
our chance of false positive results.
We used BMI as a proxy of waist circumference as a
modiﬁed metabolic syndrome criterion, similar to other
studies [10, 11]. To check the validity of this proxy we
compared the predictive power of BMI and waist circum-
ference in the sub- population with both BMI and waist
circumference measured. For one SD increase in BMI, the
HRfortype2diabeteswere2.20(95%CI1.92–2.52)inmen
and 1.94 (95% CI 1.72–2.18) in women. For waist circum-
ference, HR was 2.45 (95% CI 2.11–2.85) in men and 2.25
(95% CI 1.96–2.59) in women, respectively. In analysis of
ROC the area under curve were for the BMI model 0.73
(95%CI 0.68–0.77) and for the waist circumference model
0.74 (95% CI 0.70–0.78) in men, and 0.76 (95%CI
0.71–0.81) and 0.77 (95% CI 0.74–0.82) in women,
respectively. Our study does not support a signiﬁcant dif-
ference in predicting ability between waist circumference
and BMI. Some data show that waist circumference predicts
diabetes marginally better than BMI [20, 21], whereas other
datahaveshowntheopposite[22].Moreover,BMIandwaist
circumference have been compared as determinants of
metabolic syndrome [23]. Interestingly, these studies found
the same cut-off values for BMI corresponding to the
established NCEP waist circumference criteria as our study,
and they also did not ﬁnd waist circumference to be superior
in predicting diabetes or CVD [10, 11].
To test the impact of non-fasting triglyceride measure-
ments, we re-analysed our data using a cut off value
of C 2.28 mmol/L as used in other studies, acknowledging
non-fasting values being 20–30% higher than fasting levels
[10, 24]. The change of triglyceride cut-off did not alter our
results signiﬁcantly.
Fasting glucose was not measured at baseline in our
study, and consequently could not be included as the ﬁfth
component of the metabolic syndrome. This could possibly
attenuate our prediction of risk estimates. But studies
which included all 5 characteristics have shown that the 5th
criterion identiﬁed only an additional 1.2–2.9% of the
metabolic syndrome cases [23, 25]. Accordingly, it is
unlikely that the lack of fasting glucose affected validity.
In conclusion, half the incident cases of type 2 diabetes
in our study were missed by using a high metabolic score
for identiﬁcation. In the low risk group with a low meta-
bolic score, smoking, low level of education and in men
also physical inactivity, signiﬁcantly improved identiﬁca-
tion. This opens for targeted prevention of type 2 diabetes
for larger groups of the population at risk.
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